ABM 1383
Alternative Names: ABM-1383Latest Information Update: 28 Oct 2024
Price :
$50 *
At a glance
- Originator ABM Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer(Metastatic disease) in China
- 28 Oct 2024 No recent reports of development identified for preclinical development in Cancer(Metastatic disease) in USA
- 30 Sep 2020 ABM 1383 is available for licensing as of 30 Sep 2020. http://www.abmtx.com/